News | Neuro Imaging | July 11, 2017

Researchers Identify Visual System Changes that May Signal Parkinson's Disease

MRI reveals changes that could help differentiate Parkinsonism disorders, track disease progression and monitor patient response to drug treatment

Researchers Identify Visual System Changes that May Signal Parkinson's Disease

July 11, 2017 — Changes in the visual systems of newly diagnosed Parkinson’s disease patients may provide important biomarkers for the early detection and monitoring of the disease, according to a new study published online in the journal Radiology.

“Just as the eye is a window into the body, the visual system is a window into brain disorders,” said lead researcher Alessandro Arrigo, M.D., a resident in ophthalmology at the University Vita-Salute San Raffaele of Milan, Italy.

Parkinson’s disease is a neurodegenerative condition caused by neuronal loss in several brain structures. Parkinson’s disease is characterized by tremors, rigidity or stiffness throughout the body, and impaired balance and coordination.

“Although Parkinson’s disease is primarily considered a motor disorder, several studies have shown non-motor symptoms are common across all stages of the disease,” Arrigo said. “However, these symptoms are often undiagnosed because patients are unaware of the link to the disease and, as a result, they may be under-treated.”

Non-motor symptoms experienced by patients with Parkinson’s disease include visual alterations such as an inability to perceive colors, a change in visual acuity, and a decrease in blinking which can lead to dry eye.

“These non-motor Parkinson’s symptoms may precede the appearance of motor signs by more than a decade,” Arrigo said.

The study of 20 newly diagnosed and not yet treated patients (11 men, 9 women) with Parkinson’s disease and 20 age- and gender-matched healthy controls involved a multi-disciplinary team of researchers in ophthalmology, neurology and neuroradiology of the University of Messina, Italy. Magnetic resonance imaging (MRI) was performed on both the healthy controls and the patients, who underwent imaging within four weeks of their diagnosis. Researchers used an MRI technique called diffusion weighted imaging to assess white matter changes and voxel-based morphometry (VBM) to investigate concentration changes of brain’s gray and white matter. All study participants also had ophthalmologic examinations.

The researchers found significant abnormalities within the visual system brain structures of Parkinson’s disease patients, including alterations of optic radiations, a reduction of white matter concentration and a reduction of optic chiasm volume. The optic chiasm is the part of the brain where the left and right optic nerves intersect.

“The study in depth of visual symptoms may provide sensitive markers of Parkinson’s disease,” Arrigo said. “Visual processing metrics may prove helpful in differentiating Parkinsonism disorders, following disease progression, and monitoring patient response to drug treatment.”

Arrigo added that future studies are needed to better understand the timing of degeneration along visual pathways, as well as the specific changes.

“We’re excited by our findings,” he said. “However, this is just a starting point.”

For more information: www.pubs.rsna.org/radiology

Related Content

Distress Associated With Missed Appointments and Hospital Admission During Cancer Treatment
News | Radiation Therapy | September 26, 2017
Psychological distress has long been associated with negative health outcomes for cancer patients, though specific...
Adding Radiation to Chemotherapy May Dramatically Improve Survival for Advanced-Stage NSCLC Patients
News | Stereotactic Body Radiation Therapy (SBRT) | September 26, 2017
Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC)...
Breast Cancer Patients Largely Find Radiation Therapy Experience Better Than Expected
News | Women's Health | September 25, 2017
A new survey finds breast cancer patients’ actual radiation therapy experiences largely exceeded their expectations....
Long-Term Survival Rates More Than Double Previous Estimates for Locally Advanced Lung Cancer
News | Radiation Therapy | September 25, 2017
Long-term results of a phase III clinical trial indicate survival rates for patients receiving chemoradiation for...
Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
Siemens Healthineers to Showcase Magentom Vida MRI at RSNA 2017
Technology | Magnetic Resonance Imaging (MRI) | September 18, 2017
September 18, 2017 — Siemens Healthineers announced it will display the new Magnetom Vida 3T...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
Overlay Init